Nickan Research Institute Journal of Renal Injury Prevention 2345-2781 14 3 2025 09 01 SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends e38409 e38409 10.34172/jrip.2025.38409 EN Mohammad Memarian https://orcid.org/0000-0003-4534-3018 Rahimeh Eskandarian https://orcid.org/0000-0002-4727-3386 Journal Article 10.34172/jrip.2025.38409 2024 09 03 2024 12 27 The landscape of pulmonary hypertension (PAH) treatment is evolving, with SGLT2 inhibitors being recognized as a potential fourth treatment pathway alongside traditional therapies. Their incorporation into treatment strategies for PAH could represent a significant shift in management approaches.